Halozyme Therapeutics (HALO) Stock Forecast & Price Target

Halozyme Therapeutics is favorably positioned because 2Q26 results materially exceeded expectations, with royalty revenue of about $308MM and total revenue of $481MM, driven by broadening demand across DARZALEX, PHESGO, VYVGART, and newer launches such as OCREVUS SC, OPDIVO QVANTIG, and RYBREVANT FASPRO. The outlook is further supported by strong commercial momentum in ENHANZE, as global conversion to subcutaneous PHESO reached 54%, collaboration activity hit a record pace with four agreements in 2Q26 and a fifth in July, and management raised 2026 guidance across revenue, royalties, adjusted EBITDA, and non-GAAP EPS. Fundamentally, the platform’s durability, expanding addressable markets in ADCs and nucleic acids, and follow-on nominations from existing partners suggest a widening royalty base, while lower share count and disciplined capital deployment add to the attractiveness of the earnings trajectory.

Halozyme Therapeutics is facing a negative outlook because its valuation depends heavily on partner-driven ENHANZE and Hypercon royalties, while any technology, clinical, or regulatory setback could materially disrupt commercialization or delay approvals. The company also faces meaningful commercial and partnership risk, including competition, ongoing Merck litigation, and the possibility that programs like ORKA-001 or other ongoing candidates fail to deliver favorable efficacy or durability, undermining the thesis behind its growth. Although FY26 revenue is modeled to rise 7.9% to $1.89B and royalties 7.1% to $1.23B, the balance sheet remains a concern with about $2B in debt, high development spending, and the risk of future capital raises or dilution.